PolyTherics
Biopharmaceutical conjugation technology for therapeutic drug development.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | N/A | Acquisition | |
| Total Funding | 000k | ||
| GBP | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 50 % | 79 % | (3 %) | (39 %) | (99 %) | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (603 %) | (226 %) | (350 %) | 1539 % | (1721 %) | 307 % | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (562 %) | (188 %) | (284 %) | 1527 % | (3329 %) | 300 % | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
PolyTherics was a biopharmaceutical company founded in 2001 as a spin-out from the UCL School of Pharmacy and Imperial College London by Professor Steve Brocchini, Dr. Antony Godwin, and Dr. Sunil Shaunak. The company was established based on their research into using polymers for therapeutic purposes, specifically attaching them to proteins and antibodies to serve as a basis for new drugs. This process, known as conjugation technology, synthetically alters a bioactive molecule, such as a protein or antibody, to improve its stability and pharmacokinetic properties.
The company's core focus was providing proprietary site-specific conjugation technologies and services to the pharmaceutical and biotechnology industries to enable the development of improved biopharmaceuticals. This included technologies for creating antibody-drug conjugates (ADCs) and optimizing the therapeutic characteristics of protein-based drugs. One of its key innovations was the ThioBridge® platform, a technology for stable and site-specific conjugation, which is crucial for developing effective ADCs. Its business model involved providing R&D services and licensing its technologies to a global customer base that included major pharmaceutical companies and biotech firms, generating revenue from both services and potential future royalties.
In January 2012, PolyTherics acquired Warwick Effect Polymers. A significant milestone occurred in July 2013 when PolyTherics merged with Antitope Ltd., a leader in immunogenicity assessment and protein engineering. This merger led to the formation of a new parent company, Abzena, in May 2014, to create a single entity with a broader range of complementary services. Following the merger, PolyTherics and Antitope initially continued to trade as subsidiaries under the Abzena group. Abzena went on to be listed on the AIM market of the London Stock Exchange in July 2014 and has since expanded through further acquisitions, becoming an integrated contract development and manufacturing organization (CDMO).
Keywords: bioconjugation, antibody-drug conjugates, ADC, protein engineering, therapeutic proteins, polymer technology, biopharmaceuticals, drug development, ThioBridge, UCL spin-out, pharmaceutical services, protein stability, pharmacokinetics, site-specific conjugation, drug delivery